-
NMPA Announcement on the Revision of the Package Insert of the Oxiracetam Preparations
2021-06-24
The NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of oxiracetam preparations. On June 22, relevant issues are hereby announced as follows.
-
NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products
2021-06-18
The NMPA has organized to formulate the Requirements for Change Items and Application Dossiers of Marketed Biological Products, which has been issued and implemented on June 17.
-
NMPA Announcement on Revising the Package Insert of Misoprostol Tablets for Obstetrical and Gynecological Application
2021-02-26
To further protect public medication safety, the NMPA decided to revise the package insert of Misoprostol Tablets for obstetrical and gynecological application. Relevant issues are hereby announced as follows.
-
NMPA Notice on Issuing the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers
2021-02-24
The NMPA has organized to formulate the Requirements for Change Items of Marketed Traditional Chinese Medicines and Application Dossiers, which has been issued and implemented on February 23.
-
NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Thirty-eighth Batch)
2021-02-23
On February 20, the Catalogue of Reference Preparations of Generic Drugs (Thirty-eighth Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.
-
NMPA Notice on Issuing the Requirements for Change Items of Marketed Chemicals and Application Dossier
2021-02-10
To cooperate with the implementation of the Provisions for Drug Registration, the NMPA has organized to formulate the Requirements for Change Items of Marketed Chemicals and Application Dossier.
